These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21677283)

  • 1. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes.
    Menge BA; Grüber L; Jørgensen SM; Deacon CF; Schmidt WE; Veldhuis JD; Holst JJ; Meier JJ
    Diabetes; 2011 Aug; 60(8):2160-8. PubMed ID: 21677283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals.
    Rohrer S; Menge BA; Grüber L; Deacon CF; Schmidt WE; Veldhuis JD; Holst JJ; Meier JJ
    J Clin Endocrinol Metab; 2012 May; 97(5):E791-5. PubMed ID: 22399501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis.
    Meier JJ; Kjems LL; Veldhuis JD; Lefèbvre P; Butler PC
    Diabetes; 2006 Apr; 55(4):1051-6. PubMed ID: 16567528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.
    Kjems LL; Kirby BM; Welsh EM; Veldhuis JD; Straume M; McIntyre SS; Yang D; Lefèbvre P; Butler PC
    Diabetes; 2001 Sep; 50(9):2001-12. PubMed ID: 11522665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
    Meier JJ; Pennartz C; Schenker N; Menge BA; Schmidt WE; Heise T; Kapitza C; Veldhuis JD
    Diabetes Obes Metab; 2013 Mar; 15(3):258-63. PubMed ID: 23039360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes.
    Meneilly GS; Veldhuis JD; Elahi D
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6251-6. PubMed ID: 16091500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.
    Mezza T; Moffa S; Ferraro PM; Quero G; Capece U; Carfì A; Cefalo CMA; Cinti F; Sorice GP; Impronta F; Mari A; Pontecorvi A; Alfieri S; Holst JJ; Giaccari A
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2685-2694. PubMed ID: 30874733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
    Ito A; Horie I; Miwa M; Sako A; Niri T; Nakashima Y; Shigeno R; Haraguchi A; Natsuda S; Akazawa S; Kamada A; Kawakami A; Abiru N
    J Diabetes Investig; 2021 Aug; 12(8):1367-1376. PubMed ID: 33369175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.
    Juhl CB; Schmitz O; Pincus S; Holst JJ; Veldhuis J; Pørksen N
    Diabetologia; 2000 May; 43(5):583-8. PubMed ID: 10855533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.
    Salehi M; Aulinger B; Prigeon RL; D'Alessio DA
    Diabetes; 2010 Jun; 59(6):1330-7. PubMed ID: 20215429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.
    Basu A; Dalla Man C; Basu R; Toffolo G; Cobelli C; Rizza RA
    Diabetes Care; 2009 May; 32(5):866-72. PubMed ID: 19196896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.